-+ 0.00%
-+ 0.00%
-+ 0.00%

Generate Biomedicines starts Phase 3 SOLAIRIA trials of GB-0895 in severe uncontrolled asthma

PUBT·08/26/2026 10:04:10
Listen to the news
Generate Biomedicines starts Phase 3 SOLAIRIA trials of GB-0895 in severe uncontrolled asthma
  • Generate Biomedicines presented Phase 1 data for GB-0895, a long-acting anti-TSLP antibody being developed for asthma.
  • The readout showed durable anti-inflammatory activity with a tolerability profile consistent with placebo, supporting dosing as infrequently as twice yearly.
  • Biomarker effects appeared to plateau at the selected dose, reducing the case for higher dosing and supporting a simpler commercial regimen.
  • Two global Phase 3 trials, SOLAIRIA-1 and SOLAIRIA-2, are underway in severe uncontrolled asthma to test clinical outcomes over 52 weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-365556), on August 26, 2026, and is solely responsible for the information contained therein.